PKMYT1, a partner of the serine/threonine protein kinase family, was considered as a poor prognosis marker among many different types of tumors, such as glioblastoma [53], ovarian cancer [54], prostate cancer [55], and esophageal squamous cell carcinoma [56]. This evidence concerns the gene PKMYT1 and prostate carcinoma.